One of the main challenges in tissue engineering/regenerative medicine (TERM) is the
repair of damaged heart tissue, avoiding or minimizing ventricular remodeling which leads …

In an open-label, 24-month trial, 721 de novo heart transplant recipients were randomized to
everolimus 1.5 mg or 3.0 mg with reduced-dose cyclosporine, or mycophenolate mofetil …

Cardiac allograft vasculopathy remains a major challenge to long-term survival after heart
transplantation. Endothelial injury and dysfunction, as a result of multifactorial immunologic …

Randomized trials showed that mTOR inhibitors prevent early development of cardiac
allograft vasculopathy (CAV). However, the action of these drugs on CAV late after …

Objective—Patients with elastin deficiency attributable to gene mutation (supravalvular
aortic stenosis) or chromosomal microdeletion (Williams syndrome) are characterized by …

Background The aim of the study was to assess temporal changes in plaque size and
components after heart transplantation (HTx), and to evaluate the differences in treatment …

BACKGROUND: Despite improvements in immunosuppressive therapy, the most
advantageous combination for cardiac transplant recipients has not been established. This …

Background—Despite improvements in the care of patients who have received cardiac
transplants, coronary allograft vasculopathy (CAV) remains the most prevalent cause of late …

Introduction: Thoracic transplantation represents the definitive therapy for end-stage lung
and heart diseases. Over the life of the allograft, upregulation of profibroproliferative …

Sirolimus is used in heart transplant patients with CAV and CNI‐induced nephropathy.
However, little is known regarding the tolerability, rejection rate, and effect on renal function …